Recently, the inhibition of the degradation by the proteasome of the wild-type MLL was proposed as an alternative strategy against MPAL with the use of IRAK (interleukin-1 receptor-associated kinase) inhibitors (Figure 2, point f; Table 2). The gene discussed is IRAK1; the disease is mixed phenotype acute leukemia.